Basking Ridge, NJ, United States of America

Michael Cucolo

This inventor holds 1 USPTO granted patent. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2007.


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael Cucolo: Innovator in Pharmaceutical Chemistry

Introduction

Michael Cucolo is a notable inventor based in Basking Ridge, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations. His work focuses on enhancing the solubility and stability of pharmaceutical compounds.

Latest Patents

Cucolo holds a patent for a complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol. This invention provides a ras-farnesyltransferase inhibitor complex formed from a ras-farnesyltransferase inhibitor or a pharmaceutically acceptable salt thereof, a substituted cyclodextrin, and ethanol. The complex exhibits unexpectedly high aqueous solubility of the ras-farnesyltransferase inhibitor, improved dissolution, enhanced stability, and is essentially free of particulate matter.

Career Highlights

Michael Cucolo is associated with Bristol-Myers Squibb Company, where he applies his expertise in pharmaceutical development. His innovative approach has contributed to advancements in drug formulation and delivery systems.

Collaborations

Cucolo has collaborated with esteemed colleagues such as Anne Marie Smith and Munir N Nassar. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Michael Cucolo's contributions to pharmaceutical chemistry exemplify the impact of innovation in drug development. His patented work continues to influence the field, showcasing the importance of enhancing drug solubility and stability for better therapeutic outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…